What is ProteinQure?
ProteinQure operates at the intersection of biotechnology and high-performance computing. The company specializes in the design of novel, exotic peptides intended for broad therapeutic applications. Its core technology, ProteinStudio, utilizes sophisticated AI models and molecular simulations to engineer drug-like peptides that offer superior precision in tissue-specific delivery. By minimizing off-target effects, ProteinQure addresses critical bottlenecks in traditional drug discovery, providing a robust framework for developing next-generation therapeutics. The company's market position is bolstered by its ability to integrate computational rigor with biological validation, a combination that has attracted significant interest from both venture capital firms and established pharmaceutical partners looking to modernize their drug development pipelines.
How much funding has ProteinQure raised?
ProteinQure has raised a total of $15M across 2 funding rounds:
Angel/Seed
$4M
Series A
$11M
Angel/Seed (2019): $4M with participation from 8VC, iNovia, Golden Ventures, Felicis Ventures, Tom Williams, and Global Founders Capital
Series A (2025): $11M, investors not publicly disclosed
Key Investors in ProteinQure
8VC
A venture capital firm focused on building and investing in technology companies that solve complex, large-scale problems.
iNovia
A full-stack venture firm that partners with founders to build enduring global technology companies by prioritizing human capital.
Global Founders Capital
A global early-stage investor that supports entrepreneurs from pre-seed to IPO, providing operational support and resources for category-defining ventures.
What's next for ProteinQure?
With the successful closure of this latest financing round, ProteinQure is well-positioned to accelerate its research and development initiatives. The strategic focus will likely shift toward expanding the capabilities of the ProteinStudio platform and deepening its collaborative efforts with Tier 1 pharma partners. As the company moves deeper into the clinical validation phase, the emphasis will remain on optimizing its peptide library and demonstrating the scalability of its computational drug design model. This capital injection provides the necessary runway to transition from a research-heavy entity to a clinical-stage powerhouse, potentially setting a new standard for how exotic peptides are discovered and deployed in the global healthcare market.
See full ProteinQure company page
